INTRODUCTION
============

In the human genome trinucleotide repeats (TNR) are especially abundant in intergenic regions, gene introns and untranslated regions, and translated segments of protein coding genes. Short tandem-TNR have generally less than 30 copies in the normal population ([@B19]). Abnormal expansions of certain types of TNR result in trinucleotide repeat expansion diseases (TREDs), a group of inherited human genetic disorders involving the nervous system (**Table [1](#T1){ref-type="table"}**; [@B74]). Expansions of triplet repeats occur in coding or non-coding regions of unrelated genes and typically result in late-onset neurological diseases. Disease severity and onset are largely dependent on the expansion length. The pathogenic mechanisms associated to TNR expansions have been an extensive field of research over the last two decades. Different studies have revealed a tremendous complexity in the pathomechanisms, with diverse detrimental effects probably coexisting in cells. This complexity lies beneath the selective affectation of specific cell types in the brain, which is characteristic in each TRED.

###### 

Trinucleotide expansion diseases.

  Disease                                               Repeat type (normal vs expanded)   Gene        Gene function                                                                                                                                  Repeat in coding regions of the sense transcript   Repeat in non-coding regions of the sense transcript   Bidirectional-transcription                       RAN translation      Small repeated CNG biogenesis   Described pathogenic process
  ----------------------------------------------------- ---------------------------------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------ ------------------------------------------------- -------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Dentatorubral-pallidoluysian atrophy (DRPLA)          CAG (3--36/49--88)                 *ATN1*      Nuclear receptor correpressor                                                                                                                  PolyQ                                              \-                                                     Yes^[\*](#fn01){ref-type="fn"}^                   Unknown              Unknown                         PolyQ gain of function
  Fragile X tremor/ataxia associated syndrome (FXTAS)   CGG (6--52/60--200)                *FMR1*      Translation repressor, mRNA trafficking from the nucleus to the cytoplasm                                                                      \-                                                 5′UTR                                                  Yes (CCG expansion in the *FMR1_AS*)              Yes (PolyG)          Yes                             RNA foci sequestering MBNL, hnRNP G, hnRNPA2/B1, SAM68, Pur α , lamin A/C. Chromatin changes. Altered miRNA biogenesis
  Friedeich ataxia (FRDA)                               GAA (6--32/\>200)                  *FXN*       Biosynthesis of heme and assembly and repair of iron-sulfur clusters                                                                           \-                                                 Intron                                                 Yes *FAST-1*                                      Unknown              Unknown                         FXN loss of function, chromatin changes
  Huntington disease (HD)                               CAG (6-35/36-121)                  *HTT*       Transcription, intracellular signalling, trafficking, endocytosis, metabolism                                                                  PolyQ                                              \-                                                     Yes (CUG expansion in the *HTT_AS*)               Unknown              Yes                             PolyQ gain of function, RNA foci sequestering MBNL, sCAG biogenesis and activity
  Huntington's disease like 2 (HDL2)                    CTG (6--28/40--59)                 *JPH3*      Formation of junctional membrane complexes, which link the plasma membrane with the endoplasmic or sarcoplasmic reticulum in excitable cells   PolyL; PolyA                                       3′UTR                                                  Yes (CAG expansion in the *JPH3_AS*)              Unknown              Unknown                         RNA foci sequestering MBNL
  Myotonic dystrophy type 1 (DM1)                       CTG (5--37/50 to \>3500)           *DMPK*      Regulates the expression of muscle-specific genes                                                                                              \-                                                 3′-UTR                                                 Yes (CAG expansion in the DMPK_AS)                Yes (PolyQ)          Yes                             RNA foci sequestering MBNL, CUGBP1 activation chromatin changes
  Spinocerebellar ataxia 1 (SCA1)                       CAG (6--39/39--81)                 *ATXN1*     Gene expression regulation                                                                                                                     PolyQ                                              \-                                                     Yes^[\*](#fn01){ref-type="fn"}^                   Unknown              Yes                             PolyQ gain of function
  Spinocerebellar ataxia 2 (SCA2)                       CAG (13--33/\>34)                  *ATXN2*     Possible role in RNA metabolism                                                                                                                PolyQ                                              \-                                                     Yes^[\*](#fn01){ref-type="fn"}^                   Unknown              Unknown                         PolyQ gain of function
  Spinocerebellar ataxia 3 (SCA3)                       CAG (13--44/\>55)                  *ATXN3*     Deubiquitination, transcriptional regulation                                                                                                   PolyQ                                              \-                                                     Yes^[\*](#fn01){ref-type="fn"}^                   Unknown              Unknown                         PolyQ gain of function
  Spinocerebellar ataxia 6 (SCA6)                       CAG (13--44/\>55)                  *CACNA1A*   Calcium channel controlling neurotransmitter release and calcium homeostasis                                                                   PolyQ                                              \-                                                     Yes^[\*](#fn01){ref-type="fn"}^                   Unknown              Unknown                         Protein GOF/LOF (?)
  Spinocerebellar ataxia 7 (SCA7)                       CAG (4--35/37--306)                *ATXN7*     Component of TFTC/STAGA transcriptional coactivator complexes, regulates retinal gene expression                                               PolyQ                                              \-                                                     Yes (CUG expansion in SCAANT1) ([@B96])           Unknown              Unknown                         PolyQ gain of function
  Spinocerebellar ataxia 8 (SCA8)                       CTG (\<50/74--1300)                *ATXN8*     Unknown                                                                                                                                        Non-coding RNA                                     Non-coding RNA                                         Yes (CUG expansion in the *ATX8_OS* 3′UTR)        Yes (PolyA, PolyQ)   Unknown                         PolyQ gain of function ATX8; RNA gain of function ATX8_OS
  Spinocerebellar ataxia 12 (SCA12)                     CAG (4--32/51--78)                 *PPP2R2B*   Negative control of cell growth and division                                                                                                   \-                                                 5′-UTR                                                 Yes (CUG expansion in the*PPP2R2B~AS~*) ([@B8])   Unknown              Unknown                         Unknown
  Spinocerebellar ataxia 17 (SCA17)                     CAG (25--42/47--63)                *TBP*       Initiation of transcritption                                                                                                                   PolyQ                                              \-                                                     Yes^[\*](#fn01){ref-type="fn"}^                   Unknown              Unknown                         PolyQ gain of function

Detected according to ASSAGE sequencing in normal peripheral blood monocyteic cells (He et al., 2008). Deeper characterization of the antisense transcript is not available.

The largest group of inherited polyglutamine (polyQ) disorders is caused by expansions of CAG repeats in the open reading frame (ORF) of unique genes, including the Huntington's disease (HD) genes and several spinocerebellar ataxias (SCA) genes. In these diseases the predominant hypothesis has been that the expanded polyQ track confers detrimental properties to the protein, that compromise cell homeostasis. The consequences of polyQ expansion in the HTT protein have been systematically characterized, with detrimental effects in transcriptional activity, vesicle trafficking, mitochondrial function and proteasome activity ([@B115]). However, the view of a protein-based toxocity in polyQ disorders has been challenged, as recent findings point to an additional toxic effect of the expanded CAG in the exon 1 of *HTT* mRNA ([@B2]).

TNR expansions also occur in non-translated regions of selective genes. In myotonic dystrophy (DM1) a CTG expansion in the 3′UTR of the *DMPK* gene (50--3000 repeats) leads to neuromuscular degeneration ([@B7]). A CGG expansion (above 200 repeats) in the 5′-untranslated region (5′UTR) of the *FMR1* gene produces fragile X syndrome, the most common type of mental retardation. Yet, shorter CGG expansions (55--200 repeats) are associated to different pathologies such as fragile X tremor/ataxia syndrome (FXTAS) and primary ovarian failure (POF; [@B102]; [@B31]). Expansions occurring in non-translated regions produce RNAs with a toxic gain of function, involving a number of mechanisms, described in subsequent sections.

The recent discovery of repeat associated non-ATG (RAN) translation ([@B117]) has changed the view of TREDs pathogenesis, as toxic proteins may be also produced from expanded TNR thought to be embedded in non-coding RNAs. RAN-translation from Ataxin8 Oposite Strand (*Ataxin8_OS*) with an expanded CAG has been shown in different frames, in SCA8 mouse models and in patients with SCA8 ([@B117]). The same study showed RAN-translation across DM1 transcripts, resulting in the accumulation of PolyQ expanded proteins in DM1 mice models myoblasts and cardiomyocites. A similar phenomenon has been recently demonstrated in expanded CGG repeats in *FMR1* 5′-UTR ([@B101]). A cryptic polyglycine-containing protein (FMRpolyG) was detected accumulating in ubiquitin-positive inclusions in Drosophila, cell culture and mouse disease models, and in brains of patients with FXTAS. The relevance of this mechanism needs to be specifically addressed for each TRED.

In this review we focus on the RNA pathogenic mechanisms in TREDs. We present the existing evidences for RNA binding protein (RBP) sequestration by different expanded TNR and the linked altered biological processes. We address the possible relevance of bidirectional transcritption in TREDs loci and further discuss about the role of small non-coding RNAs in TREDs pathogenesis. Finally, we summarize the latest therapeutic strategies in TREDs, based on selective targeting of the allele with the expanded TNR.

MECHANISMS OF RNA-TOXICITY IN TREDs
===================================

Recent findings indicate that alterations of RNA sequences can lead to abnormal RNA--protein interactions, alteration of protein translation, or RNA interference (RNAi) activation, among other anomalous processes. These altered pathways contribute to disruption of normal cell function and homeostasis, eventually leading to cell degeneration.

TRINUCLEOTIDE REPEAT EXPANSIONS MODIFY ALTERNATIVE SPLICING EVENTS
------------------------------------------------------------------

In TREDs abnormal expanded TNR RNA--protein interactions results in disrupted protein conformation and inclusion formation. Sequestration of RBP by the expanded TNR leads to a loss of function of such proteins (**Figure [1](#F1){ref-type="fig"}**). Muscleblind-like splicing regulator 1 (MBNL1) and Elav-like family member 1 (CUGBP1 or CELF1) are regulators of mRNA splicing that present affinity for CUG and/or CAG repeats. In DM1, long CUG repeats lead to decreased MBNL1 activity and increased CELF1 activity in muscle cells, which results in mis-splicing events in different developmentally regulated genes including the insulin receptor (*IR*), the chloride channel (*CLCN1*) and the cardiac tropin T (*TNNT2*), which explain several aspects of DM1 symptomatology ([@B80]; [@B107]).

![**Expanded TNR induce altered mRNA splicing in TREDs.** Expanded CNG repeats sequester RBP in the nucleus that modulate exon usage during pre-mRNA maturation, including MBNL1, CELF1, p68/DDX5, hnRNP A2/B1, Pur a, Sam68. This results in altered alternative splicing in several genes, producing misslocalized or dysfunctional proteins that contribute to pathogenesis in TREDs.](fnmol-06-00045-g001){#F1}

Aberrant splicing of the bridging integrator-1 (*BIN1*) pre-mRNA has been recently described in DM1 ([@B23]). BIN1 protein is required for the biogenesis of muscle T tubules, essential for excitation-contraction coupling. Mis-splicing of *BIN1* linked to a loss of function of MBNL1, produces an inactive form of BIN1 protein. While direct interaction of MBNL1 with the CUG repeat depletes MBNL1, increased levels of CEFL1 are the consequence of an indirect effect of CUG expansion involving PKC-pathways ([@B53]). CELF1 hyper-phosphorylation mediated by PKC, leads to its increased stability and activity ([@B53]). Splicing alterations have been also reported in DM1 and SCA8 brains, with neuronal cells showing MBNL1 nuclear inclusions ([@B44]; [@B14]; [@B71]). Abnormal splicing of multiple exons in microtubule associated protein tau (*MAPT*), and exon 7 in the amyloid precursor protein (*APP)* and exon 5 in glutamate receptor *NMDAR1*, have been detected in brains of DM1 patients and mouse models ([@B44]; [@B28]) and analogous splicing alterations have been shown in SCA8 mice ([@B14]) which may explain neurological alterations in these diseases. The relevance of expanded RNA-MBNL1 interaction in DM1 is strengthened in a mouse model expressing an expanded CUG RNA that recapitulates DM1 phenotypes. In this model, partial recovery of the mis-splicing defects is achieved by reestablishing MBNL1 levels. Another recently described repeated-CUG interactor is the p68/DDX5 helicase, which is present in mutant *DMPK* foci in DM1 ([@B55]). p68/DDX5 modifies of MBNL1 splicing activity and has been proposed to influence pathogenicity in DM1.

The CGG expansions in the FMR1 5′UTR causing FXTAS may also sequester MBNL1, which is accumulated as abnormal inclusions in brain of FXTAS patients ([@B43]). Other RBPs with specific affinity for CGG repeats are Pur-α and hnRNP A2/B1, which have been found in inclusions in FXTAS models ([@B45]; [@B95]). In addition, CELF1 indirect binding to the CGG repeats through the RBP hnRNP A2/B1, leads to its loss of function ([@B95]). Loss of function of Pur-α and hnRNP A2/B1 induce neurological alterations in mice ([@B47]), suggesting their participation in FXTAS neuropathology. Recently, loss of function of the splicing factor Sam68 through binding to expanded CGG repeats has been shown in FXTAS patients, contributing to aberrant splicing of the ATPase *ATP11B* and the Survival of Motor Neuron 2, centomeric *SMN2* genes ([@B92]).

Together, these data indicate that loss of function of RBP that have affinity for expanded TNR is a common mechanism operating in TREDS and further suggest that full characterization of the set of RBP binding to different types of TNR expansions will provide insights into specific pathogenic processes.

TRINUCLEOTIDE-REPEAT EXPANSIONS ALTER miRNA BIOGENESIS
------------------------------------------------------

The most recent findings suggest that sequestration of RBP by TNR expansions has other consequences in addition to alternative splicing perturbations (**Figure [2](#F2){ref-type="fig"}**). MBNL1 and the RNA helicases p68 and p72 influence the activity of proteins involved in microRNA (miRNA) biogenesis ([@B24]; [@B81]). MBNL1 in normal conditions binds to pre-miR-1 precursor, allowing the normal production of mature miR-1. Depletion of MBNL1 in DM1 permits the activity of the processing regulator LIN28, which binds to pre-miR-1 and promotes 3′-end uridylation, thus resulting in inhibition of pre-miR-1 processing by the endonuclease Dicer. The disruption of the normal pre-miR-1 processing by MBNL1 loss of function results in increased levels of miR-1 targets, including the calcium channel CACNA1C and the gap-junction channel GJA1, which may contribute to the cardiac defects in DM1 ([@B81]). The modulatory role of p68 and p72 helicases in the miRNA-processing complex ([@B24]) suggest that analogous mechanisms may exist for these proteins.

![**Altered miRNA biogenesis in TREDs.** Expanded CNG repeats have affinity for key players of miRNA biogenesis such as DROSHA and DGCR8. Other proteins modulating the activity of DROSHA complex, such as MBNL1, p72 and p68, are also sequestered by expanded TNR. Functional depletion of these proteins leads to decreased production of mature miRNAs, which results in increased expression of miRNA targets.](fnmol-06-00045-g002){#F2}

Alterations in miRNA biogenesis pathways have been also described in FXTAS ([@B91]). The hairpin structure of the expanded CGG in the FMR1 5′UTR mRNA mimics the structure of the miRNA-precursors (pri-miRNAs). DGCR8 and its partner DROSHA, key players in miRNA-precursor processing, are sequestered by CGG-RNA repeats (**Figure [2](#F2){ref-type="fig"}**). Depletion of these processors compromises the biogenesis of many miRNAs, thus triggering downstream detrimental gene expression perturbations, which likely contribute to FXTAS pathogenesis. However, this mechanism may be tissue-dependent, as small RNA profiling in peripheral blood of FXTAS patients does not reveal a general miRNA downregulation ([@B1]).

General perturbations in miRNA biogenesis result in altered mature miRNAs expression and subsequent modifications of gene silencing, which likely contribute to disrupted cell homeostasis in TREDs.

BIOGENESIS AND ACTIVITY OF SMALL REPEATED CNG IN TREDs SENSE TRANSCRIPTS
------------------------------------------------------------------------

The hairpin structure of expanded CNG repeats ([@B26]) constitutes a substrate for Dicer, an endonuclease involved in miRNA biogenesis that excises RNA precursors to generate the mature short miRNA (**Figure [3](#F3){ref-type="fig"}**). Dicer recognizes the expanded triplet and cleaves it, producing small repeated RNAs (sCNG). *In vitro* approaches demonstrated that single stranded CGG-RNA constructs are cleaved by Dicer, producing short CGG-RNAs of approximately 21 nt (sCGG; [@B32]). Recombinant Dicer also cleaves long transcripts containing other types of long CNG repeats (CAG, CUG, CCG; [@B51]). Importantly, the Dicer-dependence of sCNG biogenesis has been demonstrated in fibroblasts of patients with DM1 (sCUG), HD (sCAG) and SCA1 (sCAG; [@B51]). In this study the authors further showed that sCNG were active as transcriptional inhibitors, since they downregulated the expression of transcripts with complementary target sequences. This inhibitory activity was dependent on Ago2, a key member of the RNA silencing machinery ([@B51]).

![**Biogenesis and activity of sCNG in TREDs.** TNR expansions produce hairpin-like structures that are recognized and cleaved by Dicer to form small RNAs with repeated TNR (sCNG). Bidirectional transcription though the expanded TNR offers another source of sCNG, where perfectly complementary double stranded mRNAs with expanded TNR are cleaved by Dicer to form sCNG. sCNG are incorporated into the RISC complex and silence genes with partial or perfect complementarity.](fnmol-06-00045-g003){#F3}

The relevance of sCNG in TREDs pathogenesis has been recently addressed in HD ([@B2]). This study confirmed the biogenesis of sCAG in a neuronal cell model expressing expanded *HTT* exon-1, and in brain samples of patients with HD or the R6/2 HD mouse model. Importantly, the fraction of small RNAs (sRNAs) derived from cells expressing expanded *HTT* exon-1 produced neuronal death. Both the biogenesis and the toxic activity of sCAG were dependent on Dicer. Similarly, transfection of sRNAs isolated from the striatum and cortex of patients with HD induced significant neuronal toxicity. This toxic effect was prevented by oligonucleotides complementary to short CAG, strongly suggesting a detrimental effect of sCAG. Furthermore, toxicity may depend on downstream silencing effects, as HTT exon-1-derived sCAG were loaded onto Ago2 complexes and knocking-down of Ago2 prevented damage. However, the sequence/structure requirements for effective silencing of sCAG-targets remain to be resolved, since similar moderate inhibition was detected in luciferase assays performed with targets harboring a perfect sCAG-complementary CTG repeat or a CAG repeat that offers an interrupted sCAG target site. Whether the detrimental properties of sCAG include silencing effect through mRNA degradation and/or translational repression, or perturb gene expression networks through other mechanisms, remains to be determined. Interestingly, this study shows that the effect of sCAG-RNAs differed depending on the cell type, with high toxicity detected in BDNF-differentiated neuroblastoma cells. In this scenario, sCAG activity may provide a mechanism contributing to tissue selective affectation. The relevance of sCNG biogenesis and activity in other TREDs is an interesting field for future studies.

BIDIRECTIONAL TRANSCRIPTION IN TREDs LOCI PRODUCE NEW PATHOGENIC PLAYERS
------------------------------------------------------------------------

Much of the transcriptome is transcribed in both directions ([@B10]). While recent data suggest that only a small part of the sense transcript produces proteins ([@B18]), the anti-sense transcripts, normally less abundant, are involved in the regulation of gene expression ([@B35]; [@B68]; [@B112]; [@B3]). Bidirectional transcription has been detected in many TREDs loci including, DM1, SCA8, FXTAS, SCA7, HDL2, and HD, suggesting a role in disease pathogenesis (**Table [1](#T1){ref-type="table"}**; [@B11]; [@B54]; [@B3]; [@B12]; [@B96]; [@B108]; [@B90]). Thus, TREDs pathogenic mechanisms typically associated with expanded toxic RNA may be complemented with those induced by abnormal expanded peptides that result from coding-antisense transcripts or by a complementary non-coding expanded RNA. For instance, in SCA8, the progressive cerebellar degeneration inducing ataxia is the consequence of a CUG expansion in the 3' end of the non-protein coding *Ataxin 8OS* mRNA ([@B49]; [@B15]). This led to the conclusion that the pathogenic mechanism was related with an expanded CUG-RNA toxic gain of function. Subsequently, bidirectional transcription was demonstrated in transgenic mice expressing the entire human locus with either normal or expanded CTG allele ([@B69]). A progressive neuronal loss was found in the lines expressing expanded CUG, with concomitant co-expression of two transcripts in opposite directions. The sense transcript produced a non-coding CUG-expanded transcript (*Ataxin 8OS*) and an anti-sense transcript resulted in a CAG expansion that was translated into a highly enriched polyQ track (*Ataxin 8*). Intranuclear inclusions immunopositive for anti-polyQ antibodies, which are typical from PolyQ diseases and CUG foci formation co-localizing with MNBL1 were detected in cerebellar cells of the mouse model and patients with SCA8 ([@B14]). Thus, both RNA and protein toxic gain of function may account for SCA8 pathogenesis.

A similar process could account for HDL2 pathogenesis that is caused by a CUG/CAG repeat expansion at the Juctophilin-3 (JPH3) locus ([@B36]), The alternatively spliced forms in the *JPH3* gene place the CUG expansion in the polyleucine or polyalanine ORFs or in the 3′UTR. A *JPH3* transcript with expanded CUG repeats produce RNA foci that co-localize with MNBL1 and induces cell toxicity ([@B84]). The existence of an anti-sense CAG transcript in the JPH3 locus was recently demonstrated, which may account for the detected polyQ proteianceous inclusions ([@B108]).

Anti-sense transcripts spanning the CGG repeat have been described in the FMR1 locus (*FMR1AS*) in human lymphoblastoma cells ([@B54]). *FMR1AS* is spliced, processed and exported from the nucleus. The regulation of *FMR1AS* expression is dependent on CGG expansion size; being silenced in full CGG mutations (CGG \> 200 nt), similar to the *FMR1* sense transcript. A recent study suggested that elevated expression levels of the sense and antisense expanded *FMR1* involving mitochondrial dysfunction participate in parkinsonism phenotype that is associated with CGG-repeat moderate expansions ([@B61]). Thus, both *FMR1* and *ASFMR1* may contribute to the variable phenotypes associated with the CGG repeat expansion.

Anti-sense transcription at the DM1 locus has also been reported ([@B11]). Both sense and antisense transcripts extending across the CAG repeat were found in independent nuclear foci in a mouse model carrying \>1,000 CTG repeats in the DM1 locus and in human tissues ([@B42]).

HTT anti-sense (*HTTAS*) transcripts have been identified that contain the repeated CAG track ([@B12]). Repeat expansion reduces *HTTAS* promoter efficiency, and therefore *HTTAS* expression is reduced in the brain of HD patients. Through knocking down the *HTTAS* transcript the authors demonstrated its regulatory activity on HTT expression. The relevance of this regulatory mechanism in HD has not been addressed. However, a possibility exists that *HTTAS* provides an expanded CUG-based pathogenic mechanism.

One interesting mechanism derived from anti-sense transcription of genes containing TNR expansions is the activation of silencing mechanisms (**Figure [3](#F3){ref-type="fig"}**). Complementary repeats can form double-stranded structures compatible with endonuclease Dicer slicing activity. This results in the formation of short repeated RNAs that are incorporated into the RISC complex, possibly driving downstream gene silencing with detrimental consequences. This mechanism has been proven in a DM1 Drosophila model, in which the toxic effect of an expanded CUG track was largely enhanced if co-expressed with a CAG expansion. The co-expression of sense and anti-sense transcripts lead to the formation of repeat-derived small interfering RNAs in a process dependent of Dicer-2 and Ago-2 ([@B113]). Similarly, flies models expressing CAG/CUG -100 nt double stranded RNAs ([@B56]) showed a Dicer 2-dependent progressive neurodegenerative phenotype.

From these results it seems clear that small double stranded RNAs are detrimental for neuronal cells. However, the relevance of bidirectional transcription derived-siRNA in human disease needs to be proven, as the expression of antisense transcripts is normally low, which may limit the formation of these products.

In summary, bidirectional transcription through repeat regions of TREDs genes likely increases the complexity of the pathogenic mechanisms underlying the disease process, including the sequestration of different RBP and the biogenesis of small repeated TNR RNAs with silencing activity.

EVIDENCES FOR RNA TOXICITY IN POLYQ DISORDERS
=============================================

Although in polyQ diseases pathogenesis has been traditionally linked to altered function of the protein, a number of evidences suggest a complementary detrimental role of the expanded RNA.

*In vitro* structure determinations of expanded CAG repeats in the mRNA context of the *HTT, ATXN1-3, ATN1*and AR genes that cause different polyQ diseases (**Table [1](#T1){ref-type="table"}**) show compatibility with double stranded hairpin formation ([@B26]). Biochemical studies further suggested that MBNL1 has similar affinity for RNA containing either CUG or CAG repeats ([@B114]). Although CAG expansions in polyQ diseases occur in the protein coding sequence, nuclear RNA inclusions accumulating MBNL1 have been detected in fibroblasts of patients with ATXN3 and HD ([@B17]; [@B71]). Alternative splicing defects similar to those observed in DM1 have been shown in these cells, suggesting that splicing alterations are likely the consequence of MBNL1 sequestration.

Expanded CAG repeats were shown to induce *in vivo* toxicity at the RNA level in Drosophila, *C. elegans* and mouse models. The *in vivo* evidence for repeated CAG RNA toxicity was first obtained in a Drosophila model of SCA3 ([@B58]). The expression of untranslated CAG repeats of pathogenic length led to neurodegeneration in the absence of a mutant polyQ protein. The expression of translated CAA or interrupted CAG repeats resulted in a less severe phenotype than the expression of translated pure CAG repeats, which supported the importance of RNA structure for toxicity.

The CAG repeat toxicity at the RNA level was also demonstrated in a worm system ([@B103]). Both CAG and CUG repeats of pathological length were shown to form nuclear foci, in which the mutant transcript colocalized with the nematode ortholog of MBNL1, CeMBL. The disease phenotype was partially reversed by CeMBL over-expression.

The expression of untranslated long CAG repeats (200 copies) was also shown to be deleterious in transgenic mice ([@B37]). Mice expressing EGFP transcripts with long CAG repeats in the 3′-UTR developed electrophysiological, histological and behavioral aberrations in the muscle. Detection of nuclear RNA foci in muscle cells in this model ([@B37]) and in the striatum of the YAC128 HD mouse model expressing full-length human *HTT* ([@B79]) further suggests toxicity through expanded CAG-RNA.

These data indicate that cell failure in polyQ diseases may be the result of both an abnormal function of the protein harboring the expanded glutamine and the altered properties of the expanded-CAG RNA. The secondary structure of the CAG-repeat in each gene context and the dynamic expression and activity of RBP may provide specific pathogenic scenarios for cell dysfunction.

miRNAs PERTURBTIONS IN TREDs
============================

MicroRNAs are small RNA molecules of 20--24 nucleotides that generally inhibit the expression of target mRNA, by a mechanism involving mRNA degradation, translational inhibition or a combination of the two (reviewed in [@B20]). miRNAs biogenesis involves processing of a primary transcript in the nucleus (pri-miRNAs) by the Drosha/DGCR8 microprocessor. This generates a precursor miRNA (pre-miRNA) that is exported to the cytoplasm by exoprtin-5, where the endonuclease Dicer cleaves it to release the double-stranded miRNA. One of these strands preferentially loads onto an RNA induced silencing complex (RISC), while the other strand is usually degraded. In animals, miRNAs recognize their targets through complementarity with the seed sequence (nucleotides 2--8 of the 5′ end of the miRNA). Hundreds of mRNA targets could exist per miRNA family and at least 30% of the mRNAs are targeted by miRNAs ([@B72]).

miRNAs are fine-tuners of gene expression with key roles in the central nervous system function and development. The first evidences for a major role of miRNAs in neurons involved *in vitro* and *in vivo* models of loss of function of Dicer, a key limiting endonuclease in miRNA biogenesis. Dicer depletion disrupts the development of the CNS, with clear effects on brain morphology and cell-type specification and differentiation. Conditional knocking-down of Dicer in specific neuronal populations in adult mice further suggests a role of miRNAs in postmitotic long-term neuronal maintenance ([@B48]; [@B87]; [@B33]). Furthermore, conditional loss of Dicer in astrocytes and oligodendrocyes causes neuronal dysfunction and degeneration ([@B93]; [@B100]). DGCR8 is one of the genes whose heterozygous deletion results in DiGeorge syndrome ([@B94]) with the majority of patients showing heart defects and developmental problems. The description of DGCR8 as key component of the microprocessor ([@B30]) highlighted that defects in miRNA biogenesis likely underlie developmental defects. Haploinsufficiency of the microprocessor member DGCR8 also compromises neuronal viability in mice ([@B98]).

Perturbations of miRNA pathways have emerged as effectors of CNS damage, contributing to impaired cell homeostasis and neuronal death. MiRNAs deregulation produces alterations in the transcriptome that impact brain function, with consequences in neurodegeneration-relevant pathways, including inflammation, oxidative stress and mitochondrial integrity. The causes of miRNA expression deregulation are diverse, including changes in the activity of transcription factors or disease-associated genes and/or alterations in miRNA biogenesis or stability ([@B75]; [@B64]). Ischemia, excitotoxicity, oxidative stress or aging are examples of harmful stimuli producing alterations in the coding and non-coding transcriptome ([@B77]; [@B109]).

Several studies point to an involvement of miRNAs in the pathogenicity associated to TREDs. The toxicity of Ataxin-3 is enhanced upon Dicer ablation in Drosophila and human cell models. The administration of a pool of sRNAs restored Ataxin-3 toxic effect, suggesting a protective role of miRNAs ([@B5]). Supporting a protective role of miRNAs in polyQ diseases, miR-34b was shown to mitigate the toxicity of Ataxin-3 in a Drosophila model ([@B60]).

The activity of disease-associated genes has emerged as one of the causes for miRNA deregulation in TREDs. Mutant HTT protein interacts with Ago2 in the P-bodies, and HTT depletion impairs miRNA mediated gene silencing ([@B86]). Strong miRNA deregulation has been detected in HD that may be in part associated with altered activity of the RE1-silencing transcription factor (REST). The expanded HTT polyQ track impedes sequestration of REST by wild-type HTT in the cytoplasm, therefore allowing its translocation to the nucleus. Mislocalization in the nucleus permits REST binding to RE1 repressor sequences thus decreasing neuronal gene expression, which triggers neuronal dysfunction. Several miRNAs with RE1 upstream binding sites are down-regulated in HD, including miR-9/miR-9\* ([@B75]). A negative feed-back loop was proposed to occur in HD, involving the activity of REST-silencing complex that is regulated through the effect of miR9 and miR-9\* on REST and Co-REST, respectively ([@B75]). High-throughput sequencing analysis has revealed strong miRNA expression deregulation in the striatum and frontal cortex of patients with HD ([@B64]). A significant enrichment of down-regulated miRNAs harboring upstream RE1 or P53 binding sites was also reported in this study, suggesting a major role of these transcriptional modulators in miRNA deregulation.

In another example, Ataxin-2 has been recently identified as a component of the miRNA pathway to regulate synapse-specific long-term-plasticity. This targets the putative relevance of ataxin-2/miRNAs in spinocerebellar ataxia neurodegeneration ([@B66]).

Significant miRNA deregulation has been also detected in pre-symptomatic versus symptomatic SCA1 mouse model cerebellum, which suggests a role of miRNAs in the evolution of the disease ([@B83]). In addition, the miRNA transcriptome has been also characterized in the muscle of a Drosophila model of DM1, expressing CTG repeats alone ([@B21]). Among the downregulated miRNAs, miR-1, miR-7, and miR-10 were confirmed in muscle of patients with DM1. Interestingly, over-expression of miR-10 extended the lifespan of CUG-expressing flies, suggesting a role in the disease.

Deregulation of miRNA specifically targeting dosage-sensitive disease genes may highlight their relevance as pathogenic biomarkers, which could be selectively targeted in therapeutic strategies. Dentatorubral-pallidoluysian atrophy (DRPLA) is caused by a CAG/polyQ expansion in DRPLA gene/protein, respectively. miR-200b and miR-429 target *REPRE* mRNA, whose protein product binds to DRPLA protein. Overexpression of REPRE induces DRPLA mislocalization. Thus, expression levels of miR-200b and miR-429 could potentially contribute to DRPLA ([@B110]; [@B46]). In another example, miR-886-3p targets the frataxin gene (*FXN*) that carries an intronic GAA. TTC triplet repeat expansion in Friedeich ataxia (FRDA; [@B63]). *FXN* mRNA and protein are decreased in FRDA. The authors found increased levels of miR-886-3p in blood and cells of patients with FRDA and further demonstrated that inhibition of miR-886-3p resulted in increases of *FXN* mRNA and protein. In addition, miR-19, miR-101 and miR-130 regulate Ataxin 1 (*ATXN1*) that causes spinocerebellar ataxia 1 (SCA1), when presenting a CAG expansion ([@B57]). The authors showed that inhibition of the activity of these miRNAs enhanced the cytotoxic activity of ATXN1 with an expanded polyQ in human cells, suggesting a miRNA mechanism modulating pathogenesis. More recently, it has been shown that, miR-144 and miR-101 play a central role in modulating the levels of *ATXN1* ([@B77]). In SCA1 patients and aging the levels of these miRNAs are increased, suggesting a role in neurodegeneration. Finally, the 3′UTR of the *FMR1* mRNA is targeted by miR-101, miR-129-5p, and miR-221 ([@B116]). Downregulation of miRNAs has been generally detected in the brain of patients with FXTAs ([@B91]) and miR-221 is also downregulated in peripheral blood of males with FXTAS ([@B1]). Thus, deregulation of certain miRNAs may contribute to upregulation of expanded *FMR1*, which has been shown to participate in FXTAS pathogenesis.

These data indicate that altered expression of specific miRNAs may contribute to TREDs pathogenesis, directly perturbing the expression of dosage-sensitive genes that are essential in the maintenance of cell homeostasis. The dynamics of miRNA alterations may define the relevance of miRNA-pathways in disease evolution.

THERAPEUTIC APPROACHES TARGETTING RNA-TOXICICITY
================================================

Several therapeutic targets in polyQ diseases such as HD involve the intervention of pathways perturbed by mutant polyQ proteins, including histone acetylation, excitotoxicity and oxidative stress ([@B13]). Mutant HTT inhibits acetyltransferases, resulting in reduced levels of acetylated histones ([@B29]) Inhibition of histone deacetylase activity (HDACs) has been proposed as a therapeutic approach, alleviating altered gene expression produced by diminished acetyltransferase activity ([@B99]; [@B29]). In addition, mitochondrial impairment and excitotoxicity have been involved in neuronal death in HD. Administration of antioxidants such as Coenzyme Q10 slow striatal atrophy in mouse models of HD ([@B4]) and delivery of growth factors and cytokines modify neuronal degeneration and prevents excitotoxic deficits in murine HD models ([@B67]; [@B76]; [@B16]). Other strategies involve lowering the amount of mutant polyQ protein by reducing its production (see below) or enhancing its clearance. In this line, increased mutant HTT protein turnover in a mouse model improves disease outcome ([@B97]).

Although targeting the mutant/expanded polyQ protein or its downstream pathogenic effectors improves disease readouts, these strategies may not impede expanded TNR RNA toxicity. Approaches aimed at blocking protein and/or RNA toxicity include the use of antisense oligonucleotides (ASOs) or RNAi (short hairpin RNAs, shRNA, double stranded siRNA or modified single stranded siRNAs), targeting the expression of the mutant gene ([@B85]; [@B105]; **Figure [4](#F4){ref-type="fig"}**). RNAi using shRNA against mutant TREDs gene mRNA and protein have been successfully used *in vivo*. Intrastriatal adenoviral-delivery shRNA targeting mutant human HTT resulted in improved neuropathology and behavioral deficits in HD mouse models ([@B34]; [@B82]). Davidson's lab later showed that miRNA expression systems to inhibit *HTT* were more efficient, overcoming unspecific toxic effects induced by shRNA expressing vectors ([@B65]; [@B6]). The therapeutic potential of 2′-O-(2-methoxy)ethyl modified ASOs targeting human *HTT* has been recently addressed ([@B50]). The intracerebral transient infusion of these ASOs resulted in the RNAse H mediated degradation of the human *HTT* mRNA, in transgenic mouse models of HD ([@B50]). Importantly, transient *HTT* reduction resulted in sustained motor and histopathological phenotypic reversal in the HD rodent models.

![**Selective targeting of the expanded allele in TREDs.** shRNA, modified ASO or siRNA directed against the expanded allele results in degradation of mutant mRNA or blockage of the mutant protein synthesis, which impedes the detrimental activities of the expanded TNR in the mRNA and the mutant protein. With this strategy the normal allele is not targeted, allowing its function.](fnmol-06-00045-g004){#F4}

Because multiple studies suggest that reducing the expression of the wild-type allele may have deleterious consequences, selective targeting of the expanded allele should be optimal ([@B73]; [@B27]; [@B41]). In polyQ diseases, single-nucleotide polymorphisms (SNPs) linked to repeat expansions that distinguish wild-type from mutant alleles offer possibilities for specific targeting by RNAi. SNP targeting has been shown in HD ([@B89]; [@B9]), SCA3 ([@B59]) and SCA7 ([@B88]). Low frequency of allele-distinguishing SNPs in the human population limits this strategy. However, several authors have shown that targeting several specific SNPs can be applied to the majority of HD patients ([@B62]; [@B78]; [@B104]).

Other potential therapeutic strategies in polyQ diseases, are based on the use of several types of modified single stranded ASOs that target the CAG expansion in the mutant *HTT* or *ATXN3* mRNA, while preserving the normal function of the wild type allele ([@B38],[@B39],[@B40]; [@B25]; [@B22]; [@B111]). The longer CAG track in the mutant allele offers more binding sites for the complementary ASOs (**Figure [4](#F4){ref-type="fig"}**). In addition, the RNA structures of the expanded CAG that differ from those of the wild type allele ([@B17]; [@B52]), may offer distinctive feature for preferential recognition of the mutant allele. In these studies, single-stranded ASOs containing locked nucleic acid (LNA) or peptide nucleic acid have been shown to selectively block the expression of mutant HTT at the protein level. This effect was not associated with extensive *HTT* mRNA degradation and LNA ASOs were shown to form stable structures with the target RNA. Although expanded RNA toxicity in HD has not been addressed, the formation of stable LNA ASOs : RNA duplexes has also the potential to block expanded CAG toxic effects in *HTT* mRNA.

Several studies have demonstrated a similar therapeutic potential of a CAG-repeat antisense or morpholino targeted to expanded-CUG in the *DMPK* mRNA ([@B70]). In cell myoblast-myotube and patient cell models a 2′-O-methyl-phosphorothioate-modified (CAG)7 ASO silenced *DMPK* expression and reduced the ribonuclear aggregates. Intramuscular administration of these ASO in a DM1 mouse model further reduced expanded RNA toxicity ([@B70]). In another study, a morpholino anti-sense (CAG)25 was shown to block the interaction of MBNL1 with the expansion in a mouse model, further dispersing nuclear RNA foci, preventing alterations in alternative splicing and preventing RNA toxicity. More recently, it has been shown that systemic administration of ASOs effectively knocked down the expression of nuclear retained-transcripts containing expanded CUG in the muscle, thus correcting the physiological, histopathological and transcriptional alterations associated to this DM1 model ([@B106]).

Together, these data suggest that in TREDs, targeting the expression and activity of the expanded allele both at the RNA and protein levels is a promising therapeutic strategy.

CONCLUSION
==========

RNA toxicity is a process underlying pathogenicity in TREDs, with TNR expansions occurring in both coding and non-coding regions of specific genes. Sequestration of transcriptionally active RBP, and RBP participating in miRNA biogenesis result in direct and indirect perturbations of the coding-transcriptome, which likely contribute to cell dysfunction. Full characterization of the repertoire of RBP in different types of TNR expansions is essential to understand common detrimental pathways in etiologically diverse neurological disorders. Studies that take into consideration the gene context may provide hints to understand disease specific aspects.

The biogenesis and activity of sCNG may contribute to TREDs pathogenesis. The gene silencing activity of these species likely trigger downstream detrimental effects, which may differ, depending on the cell type. This mechanism may complement the damaging activity of expanded protein and/or expanded RNA. Whether sCNG mechanisms are only related with gene silencing or present other activities and the real importance of sCNG mechanisms in each TRED remain to be determined.

In each TRED, the mechanistic bases for tissue specificity, with particular affectation of selective neuronal types, remain largely unknown. The different RNA-based pathogenic processes provide a number of scenarios that may underlie this specificity. These include the dynamic expression and cellular and subcellular localization of RBP, the amount of expression of the sense and anti-sense transcripts spanning the expanded TNR in each cell context, the regulation of the biogenesis and activity of sCNG in different brain areas and/or the temporal and spatial primary and secondary perturbations of the miRNA transcriptome.

The mechanistic complexity in TREDs stresses the need of additional studies to dissect the relative relevance of expanded protein- RNA-, and/or sRNAs-mechanisms in each disease. In this context, the use of modified ASOs or siRNA directed to the expanded TNR has the potential to block deleterious effects of expanded full-length RNA and derived sCNG, with concomitant inhibition of expanded protein expression.

Conflict Of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported by the Spanish Government and FEDER (Fondo Europeo de Desarrollo Regional): PN de I+D+I 2008-2011 PI081367 and PN de I+D+I 2012-2015 PI11/02036, Instituto Carlos III --ISCIII-, Subdirección General de Evaluación y Fomento de la Investigación (to Eulàlia Martí), SAF2008-00357 Ministerio de Economia y competitividad, ISCIII (to Xavier Estivill). The Spanish Government supports Eulàlia Martí (Programa Miguel Servet).

[^1]: Edited by: *Hermona Soreq, The Hebrew University of Jerusalem, Israel*

[^2]: Reviewed by: *Eran Meshorer, The Hebrew University of Jerusalem, Israel; Stefan Stamm, University of Kentucky, USA*

[^3]: ^†^ *Eulàlia Martí and Xavier Estivill have contributed equally to this work.*

[^4]: This article was submitted to the journal Frontiers in Molecular Neuroscience.
